




## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

SHIGHLANDER@FULBRIGHT.COM  
PARTNER  
DIRECT DIAL: (512) 536-3184

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

April 21, 2004

<p style="text-align: center;">CERTIFICATE OF MAILING 37 C.F.R. 1.8</p> <p>I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:</p> <p style="text-align: center;"><u>April 21, 2004</u> Date</p> <p style="text-align: right;"> Steven L. Highlander</p>
---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: Serial Number 09/998,009 entitled "CDDO-COMPOUNDS AND  
COMBINATION THERAPIES THEREOF" by Marina Konopleva et al.  
Our ref: UTSC:652US


Commissioner:

Enclosed for filing in the above-referenced patent application is:

1. Response to Restriction Requirement Dated March 24, 2004;
2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSC:652US/SLH.

Very truly yours,

  
Steven L. Highlander

SLH/cpj  
Encl: As noted

25407540.1

1635



CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date below.

April 21, 2004  
Date

Steven L. Highlander

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Marina Konopleva et al.

Serial No.: 09/998,009

Filed: November 28, 2001

For: CDDO-COMPOUNDS AND  
COMBINATION THERAPIES THEREOF

Group Art Unit: 1635

Examiner: Jon E. Angell

Atty. Dkt. No.: UTSC:652US/SLH

**RESPONSE TO RESTRICTION REQUIREMENT DATED MARCH 24, 2004**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Commissioner:


This paper is submitted in response to the Restriction Requirement dated March 24, 2004 for which the date for response is April 24, 2004. It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSC:652US/SLH.

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 1-56 and 58, *i.e.*, the Group I claims. Further, with regard to the election of species, applicant select, without traverse:

- A. Leukemic cell (claim 8) – myeloid leukemia cell (all group I claims other than claim 10 consonant with elected species; all group I claims other than claim 10 generic).
- B. Solid tumor cell (claim 10) – breast cancer cell (all group I claims other than claim 8 consonant with elected species; all group I claims other than claim 8 generic).
- C. Chemotherapeutic (claims 21-24, 44, 48, 52, 56) – LG100268 (all group claims other than claim 21 consonant with elected species; claim 24 reads on the elected species and all other group I claims other than claim 21 generic).

The examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 536-3184

Date: April 21, 2004